Neurodegenerative Diseases: From Dysproteostasis, Altered Calcium Signalosome to Selective Neuronal Vulnerability to AAV-Mediated Gene Therapy

被引:4
|
作者
Quach, Tam T. [1 ,2 ]
Stratton, Harrison J. [3 ]
Khanna, Rajesh [4 ]
Mackey-Alfonso, Sabrina [1 ]
Deems, Nicolas [1 ]
Honnorat, Jerome [2 ,5 ,6 ]
Meyer, Kathrin [7 ,8 ]
Duchemin, Anne-Marie [9 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Inst Behav Med Res, Columbus, OH 43210 USA
[2] Univ Lyon, Univ Claude Bernard Lyon 1, INSERM U1217 CNRS UMR5310, F-69677 Lyon, France
[3] Univ Arizona, Dept Pharmacol, Tucson, AZ 85716 USA
[4] NYU, Dept Mol Pathobiol, New York, NY 10010 USA
[5] Hosp Civils Lyon, French Reference Ctr Paraneoplast Neurol Syndrome, F-69677 Lyon, France
[6] Inst NeuroMyoGene, SynatAc Team, F-69677 Lyon, France
[7] Res Inst Nationwide Children Hosp, Columbus, OH 43205 USA
[8] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
[9] Ohio State Univ, Dept Psychiat & Behav Hlth, Columbus, OH 43210 USA
关键词
neurodegeneration; dysproteostasis; calcium signaling; dendritic dystrophy; gene therapy; neuronal vulnerability; CRMP3; DPYSL4; UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MOTOR-NEURON; HUNTINGTONS-DISEASE; MOUSE MODEL; DOPAMINERGIC NEURODEGENERATION; DENDRITIC PATHOLOGY; BINDING PROTEINS;
D O I
10.3390/ijms232214188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite intense research into the multifaceted etiology of neurodegenerative diseases (ND), they remain incurable. Here we provide a brief overview of several major ND and explore novel therapeutic approaches. Although the cause (s) of ND are not fully understood, the accumulation of misfolded/aggregated proteins in the brain is a common pathological feature. This aggregation may initiate disruption of Ca++ signaling, which is an early pathological event leading to altered dendritic structure, neuronal dysfunction, and cell death. Presently, ND gene therapies remain unidimensional, elusive, and limited to modifying one pathological feature while ignoring others. Considering the complexity of signaling cascades in ND, we discuss emerging therapeutic concepts and suggest that deciphering the molecular mechanisms involved in dendritic pathology may broaden the phenotypic spectrum of ND treatment. An innovative multiplexed gene transfer strategy that employs silencing and/or over-expressing multiple effectors could preserve vulnerable neurons before they are lost. Such therapeutic approaches may extend brain health span and ameliorate burdensome chronic disease states.
引用
收藏
页数:25
相关论文
共 26 条
  • [1] Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside
    Xu, Liang
    Yao, Shun
    Ding, Yifan Evan
    Xie, Mengxiao
    Feng, Dingqi
    Sha, Pengfei
    Tan, Lu
    Bei, Fengfeng
    Yao, Yizheng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [2] Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
    Cagin, Umut
    REVIEWS ON NEW DRUG TARGETS IN AGE-RELATED DISORDERS, PT II, 2021, 1286 : 213 - 223
  • [3] Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases
    Perez, Barbara A.
    Shutterly, Alison
    Chan, Ying Kai
    Byrne, Barry J.
    Corti, Manuela
    BRAIN SCIENCES, 2020, 10 (02)
  • [4] AAV-Mediated Gene Therapy for the Treatment of Retinal Diseases
    Rolling, Fabienne
    CURRENT GENE THERAPY, 2010, 10 (05) : 318 - U4
  • [5] Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
    Lin, Chujiao
    Greenblatt, Matthew B.
    Gao, Guangping
    Shim, Jae-Hyuck
    HUMAN GENE THERAPY, 2024, 35 (9-10) : 317 - 328
  • [6] AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases
    Sponton, Carlos Henrique
    Kajimura, Shingo
    EMBO MOLECULAR MEDICINE, 2018, 10 (08)
  • [7] Recent developments in recombinant AAV-mediated gene therapy for lung diseases
    Flotte, TR
    CURRENT GENE THERAPY, 2005, 5 (03) : 361 - 366
  • [8] A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
    Alsalloum, Almaqdad
    Gornostal, Ekaterina
    Mingaleva, Natalia
    Pavlov, Roman
    Kuznetsova, Ekaterina
    Antonova, Ekaterina
    Nadzhafova, Aygun
    Kolotova, Daria
    Kadyshev, Vitaly
    Mityaeva, Olga
    Volchkov, Pavel
    CELLS, 2024, 13 (20)
  • [9] AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
    van der Laan, Luc J. W.
    Wang, Yigang
    Tilanus, Hugo W.
    Janssen, Harry L. A.
    Pan, Qiuwei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (03) : 315 - 327
  • [10] Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration
    Saxena, Smita
    Caroni, Pico
    NEURON, 2011, 71 (01) : 35 - 48